

=> File .Biotech
=> s (avian cartilage?)
L1 77 (AVIAN CARTILAGE?)

=> s l1 and (extract? or purificat? or separat? or isolat?)
L2 35 L1 AND (EXTRACT? OR PURIFICAT? OR SEPARAT? OR ISOLAT?)

=> s l2 and (grind? or conduit?)
L3 2 L2 AND (GRIND? OR CONDUIT?)

=> d l3 1-2 bib ab

L3 ANSWER 1 OF 2 USPATFULL on STN
AN 2002:251735 USPATFULL
TI Kolla2-desiccated avian sternal cartilage powder
IN Stiles, Terri Lynn, Laguna Beach, CA, UNITED STATES
PI US 2002137688 A1 20020926
AI US 2001-768141 A1 20010124 (9)
DT Utility
FS APPLICATION
LREP Collagen II Nutrition, Inc., 2465 Campus Drive, Irvine, CA, 92660
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 334
AB Kolla2 powder compositions, method of preparing the compositions and use of the compositions in treating arthritic joint cartilage diseases. The compositions are orally administered to human in need of cartilage cell repair in a daily dietary supplement dosage of between about 2,400 mg and 3,600 mg.

L3 ANSWER 2 OF 2 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
AN 2000-226343 [20] WPIDS
DNC C2000-069239
TI **Extraction of avian cartilage** uses flow of edible liquid circulating in **separator**, for **extracting** of collagen, hexosamines and glycosamines.
DC B04 C03 D12 D13 D21
IN HORRIERE, C; LEGRAND, J; MOLLARD, L; MONTILLET, A; NGUYEN, T H
PA (DIAN-N) DIANA INGREDIENTS; (DIAN-N) DIANA SA
CYC 89
PI FR 2782607 A1 20000303 (200020)* 10p
WO 2000011969 A1 20000309 (200020) FR
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT UA UG US UZ VN YU ZA ZW
AU 9954263 A 20000321 (200031)
EP 1109462 A1 20010627 (200137) FR
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI
JP 2002523436 W 20020730 (200264) 11p
ADT FR 2782607 A1 FR 1998-10868 19980831; WO 2000011969 A1 WO 1999-FR2052 19990827; AU 9954263 A AU 1999-54263 19990827; EP 1109462 A1 EP 1999-940241 19990827, WO 1999-FR2052 19990827; JP 2002523436 W WO 1999-FR2052 19990827, JP 2000-567100 19990827
FDT AU 9954263 A Based on WO 200011969; EP 1109462 A1 Based on WO 200011969; JP 2002523436 W Based on WO 200011969
PRAI FR 1998-10868 19980831
AB FR 2782607 A UPAB: 20021105
NOVELTY - **Avian cartilage** is **separated** and **extracted** from the skeletons of poultry, using a flow of edible liquid circulating in a **separator**.

USE - The products may be used in human and veterinary dietetics and pharmacy, and in cosmetics. The cartilage is used as a source of collagen, hexosamines and glycosamines (claimed).

ADVANTAGE - The process gives a product that does not have bovine origins, hence the risk of contamination by prions causing BSE is eliminated. This method does not rely on manual handling, and so is capable of mass industrial use.

DESCRIPTION OF DRAWING(S) - The drawing shows the apparatus for the separation of cartilage from the bone.

Water or saline inflow 1
Pump 2
Inlet for ground bones 4
Input valve 5
Mesh below the size of the bone pieces 6
Liquid overflow 8
Sieve 9
Recirculating conduit 10
Extract for spent bones 11
Valve 12
Dwg.1/1

=> s 12 and (vessel)
L4 0 L2 AND (VESSEL)

=> s 12 and (separating vessel)
L5 0 L2 AND (SEPARATING VESSEL)

=> s 12 and (pump)
L6 1 L2 AND (PUMP)

=> d 16 bib ab

L6 ANSWER 1 OF 1 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
AN 2000-226343 [20] WPIDS
DNC C2000-069239
TI **Extraction of avian cartilage** uses flow of
edible liquid circulating in **separator**, for **extracting**
of collagen, hexosamines and glycosamines.
DC B04 C03 D12 D13 D21
IN HORRIERE, C; LEGRAND, J; MOLLARD, L; MONTILLET, A; NGUYEN, T H
PA (DIAN-N) DIANA INGREDIENTS; (DIAN-N) DIANA SA
CYC 89
PI FR 2782607 A1 20000303 (200020)* 10p
WO 2000011969 A1 20000309 (200020) FR
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT UA UG US UZ VN YU ZA ZW
AU 9954263 A 20000321 (200031)
EP 1109462 A1 20010627 (200137) FR
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI
JP 2002523436 W 20020730 (200264) 11p
ADT FR 2782607 A1 FR 1998-10868 19980831; WO 2000011969 A1 WO 1999-FR2052
19990827; AU 9954263 A AU 1999-54263 19990827; EP 1109462 A1 EP
1999-940241 19990827, WO 1999-FR2052 19990827; JP 2002523436 W WO
1999-FR2052 19990827, JP 2000-567100 19990827
FDT AU 9954263 A Based on WO 200011969; EP 1109462 A1 Based on WO 200011969;
JP 2002523436 W Based on WO 200011969
PRAI FR 1998-10868 19980831
AB FR 2782607 A UPAB: 20021105
NOVELTY - **Avian cartilage** is **separated** and

extracted from the skeletons of poultry, using a flow of edible liquid circulating in a **separator**.

USE - The products may be used in human and veterinary dietetics and pharmacy, and in cosmetics. The cartilage is used as a source of collagen, hexosamines and glycosamines (claimed).

ADVANTAGE - The process gives a product that does not have bovine origins, hence the risk of contamination by prions causing BSE is eliminated. This method does not rely on manual handling, and so is capable of mass industrial use.

DESCRIPTION OF DRAWING(S) - The drawing shows the apparatus for the **separation** of cartilage from the bone.

Water or saline inflow 1

Pump 2

Inlet for ground bones 4

Input valve 5

Mesh below the size of the bone pieces 6

Liquid overflow 8

Sieve 9

Recirculating conduit 10

Extract for spent bones 11

Valve 12

Dwg.1/1

=> s 12 and (liquid? or water? or brine?)

L7 11 L2 AND (LIQUID? OR WATER? OR BRINE?)

=> s Mollard, L?/au; Montillet, A?/au; Horriere, C?/au; Legrand, J?/au; Nguyen, T?/au

L8 13 MOLLARD, L?/AU

MONTILLET, IS NOT A RECOGNIZED COMMAND

COMMAND STACK INTERRUPTED. ENTER "DISPLAY HISTORY"
TO SEE WHICH COMMANDS WERE EXECUTED.

=> s Montillet, A?/au

L9 29 MONTILLET, A?/AU

=> s Horriere, C?/au

L10 2 HORRIERE, C?/AU

=> s Legrand, J?/au

L11 1519 LEGRAND, J?/AU

=> s Nguyen, T?/au

L12 12033 NGUYEN, T?/AU

=> s 12 and (18 or 19 or 110 or 111 or 112)

L13 1 L2 AND (L8 OR L9 OR L10 OR L11 OR L12)

=> d 113 bib ab

L13 ANSWER 1 OF 1 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN

AN 2000-226343 [20] WPIDS

DNC C2000-069239

TI **Extraction of avian cartilage** uses flow of edible liquid circulating in **separator**, for **extracting** of collagen, hexosamines and glycosamines.

DC B04 C03 D12 D13 D21

IN **HORRIERE, C; LEGRAND, J; MOLLARD, L;**

MONTILLET, A; NGUYEN, T H

PA (DIAN-N) DIANA INGREDIENTS; (DIAN-N) DIANA SA

CYC 89

PI FR 2782607 A1 20000303 (200020)* 10p

WO 2000011969 A1 20000309 (200020) FR
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SL SZ UG ZW
 W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
 FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
 LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
 TM TR TT UA UG US UZ VN YU ZA ZW
 AU 9954263 A 20000321 (200031)
 EP 1109462 A1 20010627 (200137) FR
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI
 JP 2002523436 W 20020730 (200264) 11p
 ADT FR 2782607 A1 FR 1998-10868 19980831; WO 2000011969 A1 WO 1999-FR2052
 19990827; AU 9954263 A AU 1999-54263 19990827; EP 1109462 A1 EP
 1999-940241 19990827, WO 1999-FR2052 19990827; JP 2002523436 W WO
 1999-FR2052 19990827, JP 2000-567100 19990827
 FDT AU 9954263 A Based on WO 200011969; EP 1109462 A1 Based on WO 200011969;
 JP 2002523436 W Based on WO 200011969
 PRAI FR 1998-10868 19980831
 AB FR 2782607 A UPAB: 20021105
 NOVELTY - **Avian cartilage** is **separated** and
extracted from the skeletons of poultry, using a flow of edible
 liquid circulating in a **separator**.
 USE - The products may be used in human and veterinary dietetics and
 pharmacy, and in cosmetics. The cartilage is used as a source of collagen,
 hexosamines and glycosamines (claimed).
 ADVANTAGE - The process gives a product that does not have bovine
 origins, hence the risk of contamination by prions causing BSE is
 eliminated. This method does not rely on manual handling, and so is
 capable of mass industrial use.
 DESCRIPTION OF DRAWING(S) - The drawing shows the apparatus for the
separation of cartilage from the bone.
 Water or saline inflow 1
 Pump 2
 Inlet for ground bones 4
 Input valve 5
 Mesh below the size of the bone pieces 6
 Liquid overflow 8
 Sieve 9
 Recirculating conduit 10
Extract for spent bones 11
 Valve 12
 Dwg.1/1

=> d 17 1-11 bib ab

L7 ANSWER 1 OF 11 USPATFULL on STN
 AN 2003:187474 USPATFULL
 TI Use of anabolic agents, anti-catabolic agents, antioxidant agents, and
 analgesics for protection, treatment and repair of connective tissues in
 humans and animals
 IN Henderson, Todd R., Jarrettsville, MD, UNITED STATES
 Hammad, Tarek, Baltimore, MD, UNITED STATES
 Soliman, Medhat, Minya, EGYPT
 Corson, Barbara E., Fawn Grove, PA, UNITED STATES
 Lippiello, Louis, Forest Hill, MD, UNITED STATES
 Henderson, Robert W., Baldwin, MD, UNITED STATES
 PI US 2003129261 A1 20030710
 AI US 2002-192318 A1 20020711 (10)
 RLI Continuation of Ser. No. US 1999-274881, filed on 23 Mar 1999, PENDING
 Continuation-in-part of Ser. No. US 1999-249335, filed on 12 Feb 1999,
 GRANTED, Pat. No. US 6451771
 PRAI US 1998-88205P 19980605 (60)
 US 1998-74594P 19980213 (60)

DT Utility
FS APPLICATION
LREP Covington & Burling, 1201 Pennsylvania Avenue, NW, Washington, DC,
20004-2401
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1161
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions for the protection,
treatment and repair of connective tissues in humans and animals
comprising any or all of anabolic, anti-catabolic, anti-oxidant and
analgesic agents, including aminosugars, S-adenosylmethionine,
arachadonic acid, GAGs, including pentosan, collagen type II,
tetracyclines or tetracycline-like compounds, diacerin, super oxide
dismutase, L-ergothionine, one or more avocado/soybean unsaponifiables,
and an analgesic, e.g., acetaminophen, and to methods of treating humans
and animals by administration of these novel compositions to humans and
animals in need thereof.

L7 ANSWER 2 OF 11 USPATFULL on STN
AN 2003:45308 USPATFULL
TI Low molecular weight chondroitin sulphate compound having cosmetic
activity
IN Landrein, Annie, Nantes, FRANCE
Roy, Philippe, Nantes, FRANCE
Durand, Patrick, Reze, FRANCE
Delannoy, Charles, Wimereux, FRANCE
PI US 2003032620 A1 20030213
AI US 2001-912267 A1 20010725 (9)
DT Utility
FS APPLICATION
LREP JACOBSON HOLMAN, PROFESSIONAL LIMITED LIABILTY COMPANY, 400 SEVENTH
STREET, N.W., WASHINGTON, DC, 20004
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 400
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a low molecular weight chondroitin sulphate
compound having cosmetic activity, characterised more particularly by
efficient incorporation in vitro of thymidine, glucosamine and leucine
in fibroblast macromolecules of the human cutis. Local application of
this compound stimulates fibroblast metabolism. The invention also
relates to a method of preparing the said compound.

L7 ANSWER 3 OF 11 USPATFULL on STN
AN 2002:251735 USPATFULL
TI Kolla2-desiccated avian sternal cartilage powder
IN Stiles, Terri Lynn, Laguna Beach, CA, UNITED STATES
PI US 2002137688 A1 20020926
AI US 2001-768141 A1 20010124 (9)
DT Utility
FS APPLICATION
LREP Collagen II Nutrition, Inc., 2465 Campus Drive, Irvine, CA, 92660
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 334
AB Kolla2 powder compositions, method of preparing the compositions and use
of the compositions in treating arthritic joint cartilage diseases. The
compositions are orally administered to human in need of cartilage cell
repair in a daily dietary supplement dosage of between about 2,400 mg
and 3,600 mg.

L7 ANSWER 4 OF 11 USPATFULL on STN
 AN 2002:181399 USPATFULL
 TI Method and product using sturgeon notochord for alleviating the symptoms of arthritis
 IN Aoyagi, Seiji, Kobe, JAPAN
 Demichele, Stephen J., Dublin, OH, United States
 Johns, Paul W., Columbus, OH, United States
 Mazer, Terrence B., Reynoldsburg, OH, United States
 PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
 PI US 6423347 B1 20020723
 AI US 2000-678003 20001003 (9)
 RLI Continuation of Ser. No. US 1998-169422, filed on 9 Oct 1998, now patented, Pat. No. US 6149946 Continuation-in-part of Ser. No. US 1997-887432, filed on 2 Jul 1997, now patented, Pat. No. US 5849336, issued on 15 Dec 1998
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Witz, Jean C.
 LREP Parlet, Nickki L.
 CLMN Number of Claims: 18
 ECL Exemplary Claim: 1
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
 LN.CNT 1057
 AB This invention provides a composition comprising notochord and **extracts** thereof in therapeutic amounts. The invention more specifically relates to a method of treating arthritis in mammals, more particularly rheumatoid arthritis in humans through the enteral administration of notochord, notochord **extracts** or mixtures thereof. In a preferred embodiment, collagen obtained from sturgeon is enterally administered to a human at from 1.0 .mu.g to 1.05 gms per day.

L7 ANSWER 5 OF 11 USPATFULL on STN
 AN 2000:157001 USPATFULL
 TI Method and product using sturgeon notochord for alleviating the symptoms of arthritis
 IN Aoyagi, Seiji, Kobe, Japan
 DeMichele, Stephen J., Dublin, OH, United States
 Johns, Paul W., Columbus, OH, United States
 Mazer, Terrence B., Reynoldsburg, OH, United States
 PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
 PI US 6149946 20001121
 AI US 1998-169422 19981009 (9)
 RLI Continuation-in-part of Ser. No. US 1997-887432, filed on 2 Jul 1997, now patented, Pat. No. US 5849336
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Witz, Jean C.
 LREP Dixon, J. Michael, Parlet, Nickki L.
 CLMN Number of Claims: 8
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1163
 AB This invention provides a composition comprising notochord and **extracts** thereof in therapeutic amounts. The invention more specifically relates to a method of treating arthritis in mammals, more particularly rheumatoid arthritis in humans through the enteral administration of notochord, notochord **extracts** or mixtures thereof. In a preferred embodiment, collagen obtained from sturgeon is enterally administered to a human at from 1.0 .mu.g to 1.05 gms per day.

L7 ANSWER 6 OF 11 USPATFULL on STN
 AN 1998:156955 USPATFULL
 TI Method using sturgeon notochord for alleviating the symptoms of arthritis
 IN Aoyagi, Seiji, Westerville, OH, United States

DeMichele, Stephen J., Dublin, OH, United States
Johns, Paul W., Columbus, OH, United States
Mazer, Terrence B., Reynoldsburg, OH, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 5849336 19981215
AI US 1997-887432 19970702 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Witz, Jean C.
LREP Brainard, Thomas D., Dixon, J. Michael
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1117

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a composition comprising notochord and **extracts** thereof in therapeutic amounts. The invention more specifically relates to a method of treating arthritis in mammals, more particularly rheumatoid arthritis in humans through the enteral administration of notochord, notochord **extracts** or mixtures thereof. In a preferred embodiment, collagen obtained from sturgeon is enterally administered to a human at from 1.0 .mu.g to 1.05 gms per day.

L7 ANSWER 7 OF 11 USPATFULL on STN

AN 93:78968 USPATFULL

TI Deuterated analogs of 1,25-dihydroxycholecalciferol

IN Baggiolini, Enrico G., North Caldwell, NJ, United States

Hennessy, Bernard M., Nutley, NJ, United States

Uskokovic, Milan R., Upper Montclair, NJ, United States

PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

PI US 5247123 19930921

AI US 1992-907983 19920702 (7)

RLI Division of Ser. No. US 1989-438546, filed on 16 Nov 1989, now patented, Pat. No. US 5149846 which is a division of Ser. No. US 1987-96981, filed on 14 Sep 1987, now patented, Pat. No. US 4898855

DT Utility

FS Granted

EXNAM Primary Examiner: Shaver, Paul F.

LREP Gould, George M., Johnston, George W., Coletti, Ellen Ciambrone

CLMN Number of Claims: 3

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 884

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to deuterated vitamin D analogs, and processes and intermediates for their preparation. The end products, that is the deuterated vitamin D analogs, are useful for the treatment osteoporosis and cutaneous inflammations such as psoriasis, and contact dermatitis.

L7 ANSWER 8 OF 11 USPATFULL on STN

AN 92:79035 USPATFULL

TI Deuterated analogs of 1,25-dihydroxycholecalciferol

IN Baggiolini, Enrico G., North Caldwell, NJ, United States

Hennessy, Bernard M., Nutley, NJ, United States

Uskokovic, Milan R., Upper Montclair, NJ, United States

PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

PI US 5149846 19920922

AI US 1989-438546 19891116 (7)

RLI Division of Ser. No. US 1987-96981, filed on 14 Sep 1987, now patented, Pat. No. US 4898855

DT Utility

FS Granted

EXNAM Primary Examiner: Shaver, Paul F.

LREP Gould, George M., Johnston, George W., Coletti, Ellen Ciambrone

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 896

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to deuterated vitamin D analogs, and processes and intermediates for their preparation. The end products, that is the deuterated vitamin D analogs, are useful for the treatment osteoporosis and cutaneous inflammations such as psoriasis, and contact dermatitis.

L7 ANSWER 9 OF 11 USPATFULL on STN

AN 92:47041 USPATFULL

TI Method for purifying fibroblast growth factor protein

IN Kato, Koichi, Kawanishi, Japan

Kawahara, Kenji, Izumi, Japan

Kajio, Tomoko, Minoo, Japan

PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

PI US 5120715 19920609

AI US 1989-443896 19891130 (7)

PRAI JP 1988-314168 19881212

DT Utility

FS Granted

EXNAM Primary Examiner: Griffin, Ronald W.

LREP Conlin, David G., Resnick, David S., Linek, Ernest V.

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 458

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a method for purifying a fibroblast growth factor (FGF) protein with use of a crosslinked polysaccharide sulfate. The FGF protein is preferable a mutein, in which at least one human basic FGF-constituent amino acid is substituted by at least one different amino acid. The crosslinked polysaccharide sulfate is preferably a crosslinked cellulose sulfate, a crosslinked agarose sulfate or a crosslinked dextran sulfate. According to the present invention, FGF can be highly purified on a commercial scale, and therefore preparations containing the FGF protein can be advantageously formulated.

L7 ANSWER 10 OF 11 USPATFULL on STN

AN 90:9290 USPATFULL

TI Deuterated analogs of 1,25-dihydroxycholecalciferol

IN Baggiolini, Enrico G., North Caldwell, NJ, United States

Hennessy, Bernard M., Nutley, NJ, United States

Uskokovic, Milan R., Upper Montclair, NJ, United States

PA Hoffman-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

PI US 4898855 19900206

AI US 1987-96981 19870914 (7)

DT Utility

FS Granted

EXNAM Primary Examiner: Konopka, Paul E.

LREP Gould, George M., Leon, Bernard S., Boxer, Matthew

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 938

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to deuterated vitamin D analogs, and processes and intermediates for their preparation. The end products, that is the deuterated vitamin D analogs, are useful for the treatment osteoporosis and cutaneous inflammations such as psoriasis, and contact dermatitis.

L7 ANSWER 11 OF 11 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN

AN 2000-226343 [20] WPIDS

DNC C2000-069239

TI **Extraction of avian cartilage** uses flow of

edible **liquid** circulating in **separator**, for
extracting of collagen, hexosamines and glycosamines.

DC B04 C03 D12 D13 D21
IN HORRIERE, C; LEGRAND, J; MOLLARD, L; MONTILLET, A; NGUYEN, T H
PA (DIAN-N) DIANA INGREDIENTS; (DIAN-N) DIANA SA
CYC 89
PI FR 2782607 A1 20000303 (200020)* 10p
WO 2000011969 A1 20000309 (200020) FR
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT UA UG US UZ VN YU ZA ZW
AU 9954263 A 20000321 (200031)
EP 1109462 A1 20010627 (200137) FR
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI
JP 2002523436 W 20020730 (200264) 11p
ADT FR 2782607 A1 FR 1998-10868 19980831; WO 2000011969 A1 WO 1999-FR2052
19990827; AU 9954263 A AU 1999-54263 19990827; EP 1109462 A1 EP
1999-940241 19990827; WO 1999-FR2052 19990827; JP 2002523436 W WO
1999-FR2052 19990827; JP 2000-567100 19990827
FDT AU 9954263 A Based on WO 200011969; EP 1109462 A1 Based on WO 200011969;
JP 2002523436 W Based on WO 200011969
PRAI FR 1998-10868 19980831
AB FR 2782607 A UPAB: 20021105
NOVELTY - **Avian cartilage** is **separated** and
extracted from the skeletons of poultry, using a flow of edible
liquid circulating in a **separator**.
USE - The products may be used in human and veterinary dietetics and
pharmacy, and in cosmetics. The cartilage is used as a source of collagen,
hexosamines and glycosamines (claimed).
ADVANTAGE - The process gives a product that does not have bovine
origins, hence the risk of contamination by prions causing BSE is
eliminated. This method does not rely on manual handling, and so is
capable of mass industrial use.
DESCRIPTION OF DRAWING(S) - The drawing shows the apparatus for the
separation of cartilage from the bone.
Water or saline inflow 1
Pump 2
Inlet for ground bones 4
Input valve 5
Mesh below the size of the bone pieces 6
Liquid overflow 8
Sieve 9
Recirculating conduit 10
Extract for spent bones 11
Valve 12
Dwg.1/1

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 17:14:07 ON 08 AUG 2003